Welcome to our dedicated page for Immunitybio news (Ticker: IBRX), a resource for investors and traders seeking the latest updates and insights on Immunitybio stock.
ImmunityBio, Inc. (NASDAQ: IBRX) generates frequent news as a commercial-stage biotechnology company centered on IL‑15–based immunotherapies and cell therapies. Its updates often highlight clinical data, regulatory milestones, and commercial performance for ANKTIVA, an IL‑15 receptor agonist fusion complex that the company describes as a key component of its BioShield platform.
News coverage commonly focuses on bladder cancer and non‑small cell lung cancer (NSCLC). For non‑muscle invasive bladder cancer, ImmunityBio reports results from the QUILT‑3.032 trial of ANKTIVA plus BCG in BCG‑unresponsive disease, including data on disease‑specific survival, progression‑free survival, and cystectomy avoidance. For NSCLC, press releases describe findings from QUILT‑2.023 and QUILT‑3.055, where ANKTIVA combined with checkpoint inhibitors has been associated with immune restoration, measured by absolute lymphocyte count, and linked to survival outcomes in checkpoint‑experienced patients.
Regulatory developments are another major news theme. Recent announcements include a conditional marketing authorization recommendation from the European Medicines Agency for ANKTIVA plus BCG in BCG‑unresponsive NMIBC CIS, as well as Saudi Food and Drug Authority approvals for ANKTIVA plus BCG in NMIBC CIS and for ANKTIVA in combination with checkpoint inhibitors in metastatic NSCLC, including the first approval for subcutaneous administration. These items illustrate how ImmunityBio’s news flow tracks the global expansion of ANKTIVA‑based regimens.
Investors and observers can also expect news on financial results and product revenue, particularly net product revenue and unit growth for ANKTIVA, along with cash position and capital‑raising activities disclosed in earnings releases and related Form 8‑K filings. Additional stories cover early data in glioblastoma using ANKTIVA plus NK cell therapy and the Optune Gio device, initiatives in non‑Hodgkin lymphoma and other cancers, and participation in forums such as the U.S.–Saudi Biotech Alliance Summit.
By following ImmunityBio’s news page, readers can track clinical trial progress, new approvals, and commercial trends that shape the outlook for IBRX and its IL‑15–based immunotherapy programs.
ImmunityBio (NASDAQ: IBRX) announced that its Founder, Executive Chairman and Global Chief Scientific and Medical Officer Dr. Patrick Soon-Shiong was named one of "The 100 Most Influential People in Oncology in 2025" by OncoDaily on December 29, 2025.
OncoDaily highlighted Soon-Shiong's scientific and research accomplishments and described the list as recognizing changemakers who shape oncology practice across research, patient outcomes, advocacy, philanthropy, leadership, and education. The company noted the recognition underscores Soon-Shiong's leadership and his role in advancing ImmunityBio's mission to develop transformative therapies for people living with cancer and serious diseases.
ImmunityBio (NASDAQ: IBRX) reported QUILT-3.032 cohort B (N=80) results showing long-term benefit for ANKTIVA plus BCG in BCG-unresponsive high-grade papillary-only NMIBC.
Key outcomes at 36 months: disease-specific survival (DSS) 96.0%, progression-free survival (PFS) 83.1%, and cystectomy avoidance 81.8%. The 12-month primary endpoint DFS was 58.2% (36-month DFS 38.2%). Safety across cohorts A+B (N=180) was consistent with BCG: 61% grade 1–2 TRAEs, 3% grade 3, no grade 4–5.
ImmunityBio (NASDAQ: IBRX) announced the European Medicines Agency recommended a conditional marketing authorization for ANKTIVA (nogapendekin alfa inbakicept) with BCG to treat adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS).
The EMA opinion cites a single-arm trial of 100 patients showing a 71% complete response rate, responses up to 54+ months, and average response duration of about 27 months (12-month CR 66%; 24-month CR 42%). The EMA recommendation is conditional and will be sent to the European Commission for final EU approval; ImmunityBio must provide long-term post-marketing safety and efficacy data.
ImmunityBio (NASDAQ: IBRX) released a U.S. survey (Nov 13, 2025) showing patients with non-muscle invasive bladder cancer (NMIBC) want more treatment discussions and prefer alternatives to chemotherapy.
Key findings: 18% say HCPs discuss all options most visits; 84% believe immunotherapy has fewer side effects; 72% of immunotherapy recipients are satisfied with duration of positive effects; 81% are open to new treatments; 90% would accept more frequent dosing for longer benefit.
ImmunityBio (NASDAQ: IBRX) reported strong commercial and clinical momentum for ANKTIVA on November 5, 2025.
Key metrics: Q3 2025 product revenue $31.8M (up 434% vs Q3 2024), YTD product sales $74.7M, and 467% year-to-date unit growth versus fiscal 2024. Cash and marketable securities were $257.8M as of Sept 30, 2025. Q3 net loss attributable to common stockholders was $67.3M (vs $85.7M prior year quarter); nine-month net loss was $289.5M (vs $354.4M prior year).
Clinical and program updates: 5-patient glioblastoma cohort showed 100% disease control with ANKTIVA plus Optune Gio and CAR-NK; company is initiating a randomized registration trial in second-line GBM. Enrollment began in a global randomized Phase 3 NSCLC (ResQ201A) trial. QUILT.106 and QUILT-3.032 trials reported early positive signals in lymphoma and NMIBC respectively. ANKTIVA was selected as a preferred drug by a contracting organization covering ~80 million lives.
ImmunityBio (NASDAQ: IBRX) announced breakthrough findings from its Phase 2 QUILT-3.055 study of ANKTIVA® in treating advanced non-small cell lung cancer (NSCLC) patients resistant to checkpoint therapy. The study demonstrated that ANKTIVA successfully reversed lymphopenia in 80% of patients, maintaining absolute lymphocyte count (ALC) above 1,000 cells/µL.
Key results showed median overall survival of 21.1 months in patients with ALC counts greater than 1,500 cells/µL, significantly surpassing the historical 7-9 months survival with docetaxel. The company is now conducting a Phase 3 ResQ201A trial evaluating ANKTIVA + tislelizumab versus docetaxel alone in second-line NSCLC patients.
ImmunityBio (NASDAQ: IBRX) has reported promising initial results from its pilot study combining ANKTIVA®, NK cell therapy, and Optune Gio® device in treating recurrent glioblastoma (GBM). The trial showed 100% disease control in all 5 patients, with 3 patients responding to treatment, including 2 achieving near complete response, and 2 maintaining stable disease.
The chemotherapy-free treatment demonstrated significant efficacy in increasing absolute lymphocyte count in all patients who had previously experienced lymphopenia after standard care. Based on these encouraging results, ImmunityBio is planning to initiate a Phase 2 randomized trial for second-line GBM patients.
This development is particularly significant as GBM affects approximately 12,000 Americans annually and has one of the lowest five-year survival rates among brain tumors - just 9% for patients aged 45-54 and 6% for ages 55-64.
ImmunityBio (NASDAQ: IBRX) has launched a new Phase 2 study to evaluate ANKTIVA® in patients with long COVID. The study, dubbed COVID-4.019-Long (NCT07123727), aims to assess the safety and efficacy of ANKTIVA in addressing long COVID symptoms, which affect approximately one in five American adults who had COVID-19.
The single-arm study will recruit up to 40 participants and evaluate ANKTIVA's ability to improve natural killer (NK) cell and CD8+ T cell counts. The drug is currently FDA-approved for bladder cancer treatment and is being studied across multiple cancer indications, HIV, and lymphopenia.
ImmunityBio (NASDAQ: IBRX) reported promising results from its QUILT-106 Phase I trial evaluating CD19 CAR-NK cell therapy in patients with Waldenstrom macroglobulinemia (WM), a type of non-Hodgkin lymphoma. The study demonstrated complete responses in the first two treated patients with late-stage WM using a chemotherapy-free immunotherapy approach.
The trial, conducted across three sites in South Africa, has enrolled 13 NHL patients, including three with WM. One patient achieved complete response with CD19 CAR-NK monotherapy, while another maintained complete response for six months using CD19 CAR-NK combined with rituximab. Notably, all treatments were administered in an outpatient setting with no significant toxicities reported.
ImmunityBio (NASDAQ: IBRX) announced that Houston's Michael E. DeBakey VA Medical Center has become one of the first VA hospitals in the United States to administer ANKTIVA® to veterans with bladder cancer. The treatment, recently FDA-approved, combines ANKTIVA with BCG for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
This development is particularly significant as a 2024 study revealed veterans face higher bladder cancer risks due to military exposure to carcinogenic agents. The initiative was led by urologic oncologists Dr. Jeffrey Jones and Dr. Jennifer Taylor, who were instrumental in bringing this treatment to veterans and enrolling the facility in ImmunityBio's Expanded Access Program for rBCG.